Article
Bispecific Antibodies: A Balancing Act of Promise and Complexity
November 19, 2024Authors
Topics
Community Oncology
Payers
Bispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.
Bispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed in the October 2024 Association for Value-Based Cancer Care (AVBCC) conference panel session, “Bispecific Antibodies: Where Do We Stand, and What Are the Barriers to Community Adoption?” The panel of 5 experts explored the factors limiting the use of this innovative treatment option for patients with cancer in the community setting, including:
- Significant side effects including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS);
- Publishing delays for guidelines that detail how to manage side effects;
- Significant provider time required for patient monitoring and follow-up;
- Frequency of patient visits to the ER/hospital for management of mild/moderate side effects (vs being treated by the prescribing provider); and
- Significant variation in routes of administration and dosing schedules among the different products.
The AVBCC panelists also discussed the confusing array of different recommendations for hospitalization and monitoring of patients. A review of product labels confirms this point.
A Promising Future Amidst Challenges
The market is predicted to overcome these and other challenges. In fact, 3 of the 4 panelists and the moderator in the AVBCC session expect this class will achieve prominence in 5 years. Relatedly, HMP MAI’s 2024 syndicated research shows that 59% of community practices studied already have an arrangement with a hospital to send patients for bispecific antibodies and CAR-Ts (2024 Community Oncology Annual Trend Report), and that many payers do not plan on increasing their use of utilization management for bispecific antibodies or CAR-Ts (2024 Payer Oncology Annual Trends Report).
For manufacturers, the journey toward wider bispecific antibody adoption presents both challenges and opportunities. As the market adapts to address complex clinical needs and operational demands, there is a clear chance for innovation. Manufacturers who can provide solutions for streamlined monitoring, clear guidance on administration, and efficient care pathways will be at the forefront of a significant market shift.
Please don’t hesitate to reach out if you have any questions: cvandenburg@hmpglobal.com.
The Latest
Podcast
Community Oncology Practice Economics - Podcast Part 2 of 3
In part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the operational realities of oncology practice economics.
Lee Blansett
Podcast
Community Oncology Practice Economics - Podcast Part 1 of 3
In part 1 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the current state of oncology practice economics.
Lee Blansett
Article
Navigating the 340B Maze Amid the Inflation Reduction Act
As the Inflation Reduction Act (IRA) introduces new Maximum Fair Pricing (MFP) rules, integrated delivery networks (IDNs) and manufacturers will face the complexities of navigating overlapping 340B discounts and MFPs.
Emma Bijesse
Article
Bispecific Antibodies: A Balancing Act of Promise and Complexity
Bispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.
Read MoreThe Latest
Podcast
Community Oncology Practice Economics - Podcast Part 2 of 3
In part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the operational realities of oncology practice economics.
Lee Blansett
Podcast
Community Oncology Practice Economics - Podcast Part 1 of 3
In part 1 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the current state of oncology practice economics.
Lee Blansett
Article
Navigating the 340B Maze Amid the Inflation Reduction Act
As the Inflation Reduction Act (IRA) introduces new Maximum Fair Pricing (MFP) rules, integrated delivery networks (IDNs) and manufacturers will face the complexities of navigating overlapping 340B discounts and MFPs.
Emma Bijesse
Revolutionizing Cancer Care: EOM's Second Wind and its Current Impact on Community Oncology Practices
The second Enhancing Oncology Model (EOM) application cycle closed on September 16, signaling shifts in community oncology. Explore our 2024 Community Oncology Report to understand EOM’s current impact and changes from this round.
Ashutosh Sheth
Article
Bispecific Therapies in Community Oncology: Bridging Insights from CPC+CBEx and Beyond
Explore key takeaways from CPC+CBEx on bispecific therapies, highlighting collaboration between hospitals and community practices to expand access and tackle financial challenges.
Daniel Buchenberger
Article
Community Oncology: Awareness v Action in the Face of the IRA
The Inflation Reduction Act (IRA) will significantly impact community oncology practice financials. As we approach this shift, our latest research from the 2024 Community Oncology Report reveals a current gap between awareness and action.
Emma Bijesse
Prior Authorization Requirements Continue to Impact Providers
Welcome to the August 2024 edition of our Monthly Insight Series! This month we are combining insights from 3 of our customer segment reports and reflecting on provider and payer relationships.
Emma Bijesse
Article
Notes From ATOPP: Providing Bispecific Antibody Treatments in Community Oncology
The ATOPP Summit covered a range of cutting-edge topics, including the shift toward administering cellular therapies to patients in community oncology settings.
Emma Bijesse, Daniel Buchenberger
Article
Vertical Payers: “Highly Integrated” by 2026
Welcome to our Monthly Insight Series July 2024 edition! This month we discuss our 2024 research regarding the ever-rising integration across vertical payers’ health plans, PBMs, and SPs, including around manufacturer contracting.
Chris Van Denburg
Article
Oncology Clinics Frustrated With Manufacturer Engagement Tactics
Welcome to the June 2024 edition of our Monthly Insight Series! This month we’re discussing oncology clinic concerns with existing manufacturer engagement approaches, using data drawn from our 2024 Community Oncology report, coming later in June.
Ashutosh Sheth
Article
When Do Payer Pathways Matter?
While provider-initiated oncology clinical pathways are regaining momentum, payer pathways struggle to find a foothold in this space. Still, they can exert impact under certain conditions.
Cindy Chen
Article
IDNs’ Numerous Strategies and Tools to Manage High-Cost Drugs
Welcome to the May 2024 edition of our Monthly Insight Series. This month we’re exploring the new tools IDNs have deployed to monitor high-cost drugs. This is a preview of findings from our 2024 IDN Oncology Trend Survey, coming at the end of May.
Emma Bijesse
Article
Following the Money: Rx Revenues Underpin Community Oncology Business Models
Welcome to the April 2024 edition of our Monthly Insight Series. This month we’re looking at community oncology practices’ reliance on buy-and-bill drug revenues.
Lee Blansett
Article
IDN Financial Incentives: Impact on Treatment Prices?
Navigating IDNs requires understanding their financial drivers, revenue streams, and cost management. Here, we look at IDNs' key financial aspects, such as revenue optimization strategies, and examine the potential effects of site-neutral payment reforms.
Emma Bijesse
Article
Provider Economics Drive Oncologist Consolidation
Welcome to the March 2024 edition of our Monthly Insight Series. This month we examine the trend of oncologists consolidating into IDNs and network aggregators.
Article
An Update on What You Need to Know About Pathways
Welcome to the February 2024 edition of our Monthly Insight Series, featuring key findings from our recent column in the Journal of Clinical Pathways. The column was the first in a series on oncologists' awareness and use of pathways.
Lee Blansett
Article
Oncology Insights: Clinical Decision Support
Welcome to the January 2024 edition of our Monthly Insight Series. This month we are discussing clinical decision support systems in oncology.
Chris Van Denburg
Article
Oncology Insights: Notable Quotes from Key Decision Makers
Welcome to the December 2023 edition of our Monthly Insight Series. This month we are discussing standout quotes from discussions we had this year, and how they impact our key customer segments.
Chris Van Denburg, Cindy Chen
Article
What's Going On with Oncology Pathways? Here's What You Need to Know
Welcome to the November 2023 edition of our Monthly Insight Series. This month we are highlighting a few key findings from our recently published report on Oncology Clinical Pathways.
Lee Blansett
Article
Payer Insight: It’s NOT All About Drugs
Welcome to the October 2023 edition of our Monthly Insight Series. This month we highlight a specific finding from our 2023 Payer Annual Oncology Trend Report that was just released in September: Payers’ top cancer cost targets.
Chris Van Denburg
Article
Summer 2023 Recap: Here’s What You Missed From MAI
Welcome to the September 2023 edition of our Monthly Insight Series. This month we are giving a quick overview of the various reports we’ve released to our clients this summer—it’s been a busy one!
Article
Oncology Network Aggregators: Gaining Popularity?
Welcome to the August 2023 edition of our Monthly Insight Series. This month we take a deeper look into independent community oncology practices’ evolving interest in joining oncology network aggregators.
Article
The Enhancing Oncology Model: What Lies Ahead for Participants?
CMMI has launched its new oncology pilot, the Enhancing Oncology Model, sparking questions about its new features vs the Oncology Care Model, the benefits and concerns for participating practices, and CMMI’s ability to successfully implement the program.
Article
IDN Pharmacy Performance Metrics: Opportunities for Manufacturers to Engage
Welcome to the July 2023 edition of our Monthly Insights Series. This month we want to share some more thoughts on opportunities for manufacturer engagement with IDN stakeholders—the IDN pharmacy/pharmacists, in particular.
Cindy Chen
Article
Clinical Pathways Impact on Treatment Selection
As more providers explore clinical pathways as a tool for increasing clinical consistency and quality, we need to examine adoption benefits and challenges, provider compliance, and potential access risks for manufacturers.
Lee Blansett
Article
CONFLICTED: Payer Pathways vs Their Own Coverage Policies
Welcome to the May 2023 edition of our Monthly Insight Series. This month we are examining how Payers’ oncology pathways sometimes conflict with their own coverage policies, and how they can differ but still be aligned from a Payer perspective.
Chris Van Denburg
Article
Medicare Advantage Growth Will Bring Changes for Cancer Drug Manufacturers
Changes to Medicare, including Medicare Advantage, have important repercussions on patient access to care, oncologists’ treatment decisions, and drug manufacturers’ processes.
Lee Blansett
Article
Pharmacists’ Shifting Meeting Preferences
Welcome to the April 2023 edition of our Monthly Insight Series. This month we are evaluating the desire among oncology pharmacists to return to in-person meetings.
Cindy Chen
Article
Humana Quits Commercial
Welcome to the March 2023 edition of our Monthly Insight Series. This month we discuss how Humana terminated its employer group line of business and the implications.
Chris Van Denburg
Article
HMP Global Market Access Insights’ 2023 Research Year
We want to give you a look at some of the topics we’re planning to explore this year, as we enter yet another period of rapid change, upheaval, and uncertainty in 2023-2025.
Lee Blansett